Skip to main content
Fig. 4 | BMC Medicine

Fig. 4

From: Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC

Fig. 4

Nomograms were constructed for predicting the risk of 12-month and 18-month progression-free survival (PFS) (A). Survival analyses of the training cohort A (B, C) and validation cohort B (D, E) were performed using Kaplan-Meier curves to compare the PFS of patients in the T group (B, D) or A+T (C, E) group, which were further subgrouped according to the median score into low-risk (< median score) and high-risk (≥ median score)

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us